Eli Lilly's incretin manufacturing facility at Research Triangle Park in North Carolina
The obesity drug race is being fought on the manufacturing floor as GLP-1 rivals make plans to catch leaders
Ever since the weight loss drug craze created near-unprecedented demand, the first two companies to market have been doing everything they can to meet it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
